Early-stage focus Sanderling specializes in seed and early-stage financing with active management. This presents an opportunity to discuss tailored funding partnerships, interim operating support, and portfolio acceleration services for new biomedical ventures.

Biotech expertise The firm has a long track record of investing in biotechnology and biomedical ventures, including companies like ViaCyte and Glycomine. A sales angle could highlight co-development, regulatory navigation, and technical advisory offerings.

Hands-on value Sanderling emphasizes active management, cost-control strategies, and management leadership. Propose value-added services such as interim leadership, governance support, and strategic planning to improve burn rate and milestone execution.

Network leverage With a history of notable exits and broad investor involvement, there is potential to offer access to a curated network of co-investors, strategic partners, and potential acquirers to de-risk rounds and accelerate exits.

Funding trajectory Revenue range and client activity indicate ongoing fundraising and portfolio expansion opportunities. Position new diagnostic, therapeutic, or platform technologies that align with early-stage needs and long-term commitment.